A gut microbiome bacterium, *Turicibacter*, linked to reduced weight gain in mice

Obesity is closely tied to metabolic diseases such as type 2 diabetes, which affects millions of people worldwide, and it is also associated with elevated risks of heart disease. A key player in this story is the gut microbiome-the vast community of bacteria, fungi and other microbes living in the human gut-which can strongly influence metabolic health. Crucially, the relationship runs both ways: diet continually reshapes the gut microbiome, and those microbial shifts can, in turn, affect how the body handles fat and sugar.

Previous research has repeatedly connected low gut microbiome diversity with obesity. Along the same lines, animals fed a high-fat diet tend to show a drop in microbiome diversity, suggesting that dietary patterns may favour microbial communities linked to poorer metabolic outcomes.

University of Utah study highlights Turicibacter and metabolic health

In a new study led by microbiologists at the University of Utah, researchers identified a single gut bacterium-Turicibacter-as having an unusually large impact on weight gain and metabolic measures in mice eating a high-fat diet.

“I didn’t think one microbe would have such a dramatic effect – I thought it would be a mix of three or four,” said June Round, a microbiologist at the University of Utah.

The findings raise the possibility that supplements based on molecules produced by Turicibacter could, one day, help lessen some of the health consequences of obesity in humans.

Turicibacter in the gut microbiome: abundance and protective community

Within the wider gut microbiome landscape, Turicibacter sits inside a metabolically protective group of microbes that includes at least 80 bacterial species. In that microbial milieu, Turicibacter is present at a relative abundance of roughly 0.1 per cent-small in proportion, but potentially outsized in effect.

Fatty acids, ceramides and the small intestine

A major reason Turicibacter drew attention is the chemistry it produces. The bacterium generates a set of fatty acids that help keep more harmful fat molecules under control. Those harmful molecules are known as ceramides: they rise in response to a high-fat diet and are linked to metabolic diseases including type 2 diabetes and heart disease.

The fatty acids made by Turicibacter appear to deliver several metabolic benefits by influencing how fat is absorbed in the small intestine, helping to shift the balance away from pathways associated with poorer metabolic outcomes.

Why a high-fat diet can suppress Turicibacter

If Turicibacter supports healthier metabolism, could it allow someone to eat freely-say, to overindulge in chocolate cake-while staying comparatively lean? Unfortunately not. Turicibacter populations change with diet, and an environment that is too fatty can impede the growth of this beneficial bacterium.

In one experiment, Turicibacter growth stopped when palmitate was present. Palmitate is a major saturated fat component commonly found in high-fat diets. Notably, palmitate did not kill Turicibacter; once the bacterium was removed from the palmitate-rich setting, it restarted its normal growth cycle.

Because Turicibacter can buffer some of the harms of high-fat diets yet is also depleted by them, the study suggests that its levels would need to be maintained through regular supplementation.

Supplementation effects: weight gain, glucose and lipid profiles in mice

When researchers provided mice with an oral Turicibacter supplement five days a week, the animals showed multiple improvements despite continuing on a high-fat diet. Compared with controls, supplemented mice demonstrated:

• Less weight gain
  
• Lower resting glucose levels
  
• Reduced body fat
  
• Other favourable shifts in lipid profiles

These outcomes make the work medically intriguing, but the authors emphasise that further research is needed to determine whether the same effects translate to humans. Gut microbe science remains complex and rapidly evolving-often likened to an “iceberg”, where only a small portion has been uncovered so far.

How the findings fit with earlier gut microbe research

This study adds to a growing body of evidence linking the gut microbiome with metabolic health and obesity. In one earlier experiment, gut microbes taken from obese mice were transferred into lean mice that had no gut microbiome of their own; after the transfer, those previously lean mice gained weight.

In another study that may seem counterintuitive, mice whose gut bacteria had been completely wiped out gained less weight on a fatty diet than mice with normal microbiomes. That result supports the idea that particular microbial mixes can contribute to weight gain and increased body fat.

Beyond one bacterium: building a therapeutic toolbox

Turicibacter is unlikely to be the only helpful partner. Expanding the list of beneficial microbes-and, as researchers put it, “weaponising” their lipids-could widen future treatment options for metabolic diseases by targeting multiple pathways at once.

“With further investigation of individual microbes, we will be able to make microbes into medicine and find bacteria that are safe to create a consortium of different bugs that people with different diseases might be lacking,” said Kendra Klag, a microbiologist at the University of Utah and first author of the study.

A practical next step for the field is working out how to deliver such therapies reliably: ensuring microbes survive processing, storage and stomach acidity, and confirming they can establish or persist long enough in the gut microbiome to have an effect. Researchers also need to clarify which patient groups are most likely to benefit, given that baseline microbiome composition can vary widely between individuals.

Customised bacterial therapy compared with Ozempic

Unlike the current surge of interest in Ozempic and similar drugs, bacterial therapy could, in principle, be tailored to a person’s specific needs while minimising side effects-partly because these bacteria and their lipids are already found in human guts. Even so, moving from mouse studies to human use will require careful testing for safety, dosing, consistency of manufacturing and real-world effectiveness.

This research is published in Cell Metabolism.